Kuryata, Olexandr and Sirenko, Oksana and Tykhomyrov, Artem and Yatsenko, Tetyana (2021) Plasminogen Activator Inhibitor‑1 and Circulating Ceruloplasmin Levels in Men with Iron‑Deficiency Anemia and Heart Failure with Concomitant Prostate Cancer and Their Dynamics after Treatment. Journal of Medical Sciences, 42 (2). pp. 72-80. ISSN 1011-4564 (Print), 2542-4939 (Online)
![[img]](http://repo.dma.dp.ua/style/images/fileicons/text.png) |
Text
JMedSci42272-2616795_071607.pdf Download (987kB) |
Abstract
Introduction: The aim was to determine the activity of plasminogen activator inhibitor-1 (PAI-1) and levels of circulating ceruloplasmin (CP) in men with iron‑deficiency (ID) anemia and heart failure with preserved ejection fraction (HFpEF) with concomitant prostate cancer and their dynamics after intravenous iron hydroxide sucrose supplementation. Materials and Methods: Dynamic observation and treatment was performed in 53 men with ID anemia and HFpEF with concomitant prostate adenocarcinoma. Serum PAI‑1 activity levels were determined using a modified colorimetric method of tissue-type plasminogen activator determination. Serum CP levels were evaluated by immunoblot assay. Results: After 10 days of treatment in the group of patients treated with intravenous iron (III) hydroxide sucrose, the median PAI-1 activity level decreased by 9.2% (P < 0.001), in Group II, this indicator was not significantly different. After 10 days of treatment, it was estimated decreased median CP level by 35% (P < 0.001), in comparison with standard therapy – on 14.4% (P < 0.001). Conclusions: The infusion of intravenous iron (III) hydroxide sucrose in men with ID anemia and HFpEF with concomitant prostate cancer contributed to a significant decrease of PAI‑1 activity level and CP level.
| Item Type: | Article |
|---|---|
| Additional Information: | How to cite this article: Kuryata O, Sirenko O, Tykhomyrov A, Yatsenko T. Plasminogen activator inhibitor‑1 and circulating ceruloplasmin levels in men with iron‑deficiency anemia and heart failure with concomitant prostate cancer and their dynamics after treatment. J Med Sci 2022;42:72‑80. |
| Uncontrolled Keywords: | Plasminogen activator inhibitor‑1, circulating ceruloplasmin, iron‑deficiency anemia, HF with preserved ejection fraction, prostate cancer, intravenous iron supplementation. |
| Subjects: | Clinical medicine |
| Divisions: | Departments > Department of Internal Medicine 2 and phthisiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 11 Jan 2022 13:48 |
| Last Modified: | 20 May 2022 07:33 |
| URI: | http://repo.dma.dp.ua/id/eprint/7292 |
Actions (login required)
 |
View Item |
